Testing companies reducing offerings

Recently two companies quietly scaled back their offerings. OneOme scaled back their RightMed reports to make recommendations from ~300 drugs to ~30 drugs. Genesight also removed their analgesic and ADHD panels.

This may be sparked by the recent warning from the FDA to Inova that ultimately led to termination of pharmacogenetic testing services.

While the cessation of reporting of gene-drug interactions that are not currently considered actionable is desirable, will there be unintended ripple effects for other labs performing clinical genotyping? What are implementers’ opinions on these developments?

For more reading on CPIC leadership response to the FDA’s warning, see this PharmGKB blog post